Company news

Invex Therapeutics Ltd. news in 2022

Invex Therapeutics Ltd.'s news releases, calls and decks from 2022, newest first.

View company

Invex Receives Approval for Paediatric Plan from the EMA

December 13, 2022

MEDSAFE and Ethics Approval for IIH EVOLVE Trial in NZ

November 24, 2022

First Patient Randomised in IIH EVOLVE Phase III Trial

November 20, 2022

Invex Receives $0.46 Million R&D Tax Rebate

October 31, 2022

First UK Clinical Site Activated in IIH EVOLVE Phase 3 Trial

October 23, 2022

First Australian Site Activated in IIH EVOLVE Phase 3

October 23, 2022

Second HREC Approval for IIH EVOLVE Phase III Clinical Trial

September 29, 2022

4E and Annual Report to shareholders

August 18, 2022

Invex receives IND approval

August 18, 2022

Quarterly Activities/Appendix 4C Cash Flow Report

July 5, 2022

HREC and TGA Approval to Commence Phase 3 in Australia

July 3, 2022

Invex Receives UK Approval to Commence Phase III Trial

June 28, 2022

Half Yearly Report and Accounts

February 22, 2022

New Executive Director and Chairman Agreements

January 30, 2022

Decks in 2022